![Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ... Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ...](https://ars.els-cdn.com/content/image/1-s2.0-S1470204513705540-gr2.jpg)
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ...
ΜΑΜΟΥΝΑΣ ΙΩΑΝΝΗΣ | Διδάκτωρ Της Ψυχιατρικής Του Πανεπιστημίου Αθηνών - Άγχος - Αγχώδεις Διαταραχές – Κατάθλιψη - Αϋπνία & Άλλες Διαταραχές Ύπνου - Γνωσιακή Ψυχοθεραπεία - Θεραπεία Οικογένειας – Ζεύγους-Ψυχαναγκασμοί - Βουλιμία - Ανορεξία, Ψυχίατροι ...
![Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6603945/MediaObjects/41416_2007_Article_BF6603945_Fig1_HTML.gif)
Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer
![Ioannis MAMOUNAKIS | Research Associate | Doctor of Philosophy Computer Engineer and Informatics | The Centre for Research and Technology, Hellas, Thessaloníki | Chemical Process and Energy Resources Institute (CPERI) Ioannis MAMOUNAKIS | Research Associate | Doctor of Philosophy Computer Engineer and Informatics | The Centre for Research and Technology, Hellas, Thessaloníki | Chemical Process and Energy Resources Institute (CPERI)](https://i1.rgstatic.net/ii/profile.image/820006984105985-1572516308606_Q512/Ioannis-Mamounakis-2.jpg)
Ioannis MAMOUNAKIS | Research Associate | Doctor of Philosophy Computer Engineer and Informatics | The Centre for Research and Technology, Hellas, Thessaloníki | Chemical Process and Energy Resources Institute (CPERI)
![PDF) Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG) PDF) Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG)](https://i1.rgstatic.net/publication/268450818_Dose-dense_paclitaxel_versus_docetaxel_following_FEC_as_adjuvant_chemotherapy_in_axillary_node-positive_early_breast_cancer_a_multicenter_randomized_study_of_the_Hellenic_Oncology_Research_Group_HORG/links/551ebe220cf29dcabb07a69b/largepreview.png)